BABA vs CRI

The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.

CRI exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a robust current ratio of 2.51, indicating low immediate insolvency risk. While the stock is attractively valued relative to the sector (P/E 14.70 vs 35.14) and trades near its Graham Number of $38.02, it is hampered by a long-term bearish price trend (-55.4% over 5 years) and sluggish earnings growth. The disconnect between strong balance sheet health and poor price performance suggests a value trap scenario unless growth accelerates. Overall, the company is a stable 'Hold' with limited immediate catalysts for a breakout.